ArticleJACC. Advances2026
Evaluation of a Meds-to-Beds Program to Reduce Readmissions After Percutaneous Coronary Intervention.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnplanned hospitalizations following percutaneous coronary intervention (PCI) are common and represent an opportunity to improve outcomes and reduce costs. However, health system interventions to reduce readmissions in this population are not well described.
objectivesWe aimed to implement a meds-to-beds program and evaluate its impact on 30-day readmissions.
methodsWe performed an observational study among a medically underserved diverse cohort of adults who received emergent or elective PCI at an academic medical center in Bronx County, NY. The meds-to-beds program consisted of a pharmacist-directed counseling and a free, 1-month supply of dual antiplatelet therapy before discharge. The intervention was compared to the standard of care control group that received instructions and dual antiplatelet therapy prescriptions at discharge. The primary outcome was 30-day all-cause hospital readmissions. Secondary outcomes included 30-day cardiac-related readmissions and provider satisfaction.
resultsA total of 662 patients were included. In a multivariable analysis, 30-day all-cause readmissions did not differ between the intervention and control groups with respective incidences of 9.0% and 9.7% (OR: 1.07; 95% CI: 0.58-1.97). Although the 30-day cardiac-related readmission rate was significantly lower in the intervention group (2.9%) compared to the control group (6.3%), this association did not remain significant after confounder adjustment (OR: 0.50; 95% CI: 0.21-1.18). Providers perceived that the intervention improved safety and quality during transitions of care.
conclusionsA meds-to-beds program was not associated with readmission reduction among adults who received PCI. Other measures, such as medication adherence and patient satisfaction, could be employed to assess the effectiveness of future medication delivery programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.